Ann: Half Yearly Report and Accounts, page-7


I've surfaced from my short break but only to show my highlights.

"We look forward to moving swiftly into the Phase 2 study where we will obtain further safety data as well as efficacy."

They sound confident that Phase 1 will be successful and allow them to move into Phase-2 - Great.

-----------------------------

The company's arginine modulator could prove to be beneficial in the tumor microenvironment to optimize cancer-fighting immunity along with the mimotopes that induce B-Cell antibodies.


An NHMRC grant has been submitted with the Baker Heart and Diabetes Institute being a co-applicant.

I'm sure they will be looking at running pre-clinical trials with the arginine modulator in combination with Her-vax and or the new mimotope candidates - Fingers crossed for the grant.

-----------------------------


The focus of the company’s operations in the short to medium term will be directed at the gastric cancer clinical trial in 2018.

An equal priority is to identify mimotope candidates to increase our B-Cell peptide vaccine franchise and pipeline

Professor Ursula Wiedermann (our CSO) with her team at the Medical University of Vienna are working diligently to identify the next mimotope candidate for formal development.


Working diligently to lock down other mimotope candidates and add to Imugene's IP. Once again this goes to show they believe they are on the right path.